Eliot Forster - 03 Sep 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Director
Signature
/s/ Joseph R. Magnas, Attorney-in-Fact
Issuer symbol
PLX
Transactions as of
03 Sep 2025
Net transactions value
$0
Form type
4
Filing time
04 Sep 2025, 17:00:24 UTC
Previous filing
15 Sep 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Forster Eliot Director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL, ISRAEL /s/ Joseph R. Magnas, Attorney-in-Fact 04 Sep 2025 0001831558

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +7,500 7,500 03 Sep 2025 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +15,000 $0.000000 15,000 03 Sep 2025 Common Stock 15,000 $1.64 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
F2 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
F3 Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033,